HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?
Authors:
- Tatiana KekeevaTKTatiana Kekeeva
- Yulia AndreevaYAYulia Andreeva
- Alexander TanasATAlexander Tanas
- Alexey KalinkinAKAlexey Kalinkin
- Svetlana KhokhlovaSKSvetlana Khokhlova
- Tatiana TikhomirovaTTTatiana Tikhomirova
- Alexandra TyulyandinaATAlexandra Tyulyandina
- Anatoly PopovAnatoly Popov
- Maria KuzmenkoMKMaria Kuzmenko
- Mikhail VolkonskyMVMikhail Volkonsky
- Natalia ChernorubashkinaNCNatalia Chernorubashkina
- Valeria SaevetsVSValeria Saevets
Open Access
- 22 June 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 10497
Abstract
Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice. The HRD status, including the BRCA status and genomic scar score (GSS), was analyzed in 452 ovarian cancer specimens. The successful rate of HRD testing was 86% (388/452). The BRCA mutational rate was 29% (114/388); 252 samples (65%) were classified as HRD-positive. Our data demonstrate the feasibility of internal HRD testing by the AmoyDx HRD Focus Panel for high-grade serous ovarian cancer (HGSOC), showing results similar to other methods. The HRD rate in the Russian population is very similar to those of other European populations, as is the BRCA mutation frequency. The most substantial contribution to HRD level diversity is testing criteria depending on intrahospital arrangements. The analysis shows that biallelic BRCA alterations had higher GSS compared with those with monoallelic inactivation, consistent with positive HRD status. The study indicates that grades 1–2 of the pathological response caused by chemotherapy affect HRD scores and suggests controlling for tumor purity of 40% or more as a critical factor for GSS measurement.Keywords
Funding Information
- Ministry of Science and Higher Education of the Russian Federation (№ 075-15-2021-1061, RF 193021X0029)
This publication has 26 references indexed in Scilit:
- Abstract 1241: Profile of BRCA1/BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR studyCancer Research, 2018
- Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian CarcinomaMolecular Cancer Research, 2018
- Nkx2.8 Inhibits Epithelial–Mesenchymal Transition in Bladder Urothelial Carcinoma via Transcriptional Repression of Twist1Cancer Research, 2018
- Advances in ovarian cancer therapyCancer Chemotherapy and Pharmacology, 2017
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signaturesNature Medicine, 2017
- Epidemiology of ovarian cancer: a reviewCancer Biology & Medicine, 2017
- The estimation of tumor cell percentage for molecular testing by pathologists is not accurateLaboratory Investigation, 2014
- A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer CellsPLOS ONE, 2012
- Two genetic hits (more or less) to cancerNature Reviews Cancer, 2001